Granted Patent
B2
US 7,667,039 · App. 11/913,788 · Granted Feb 23, 2010
1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors
Assignee:
Novartis AG
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to novel organic compounds of formula (I) processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment of an inflammatory or obstructive airway disease, such as asthma, disorders commonly occurring in connection with transplantation, or a proliferative disease, such as a tumor disease.
Claims (2)
1. 2-Methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl,2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile.
2. 4-Toluenesulfonic acid 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl,2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile salt.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 25, 2009
From: GARCIA-ECHEVERRIA, CARLOS; STAUFFER, FREDERIC; FURET, PASCAL
To: NOVARTIS AG
Reel/Frame 023569/0263 →
Priority Claims (1)
GB 0510390.8
· May 20, 2005
· national
Continuity (1)